Trial · NCT00892177
Adverse events1,338
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,338
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Phase I: Dose Level 0 | 3 | 3 | 28 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Phase I: Dose Level 1 | 2 | 4 | 24 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Phase I: Dose Level 2 | 2 | 3 | 22 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Phase I: Dose Level 3 | 5 | 6 | 20 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Phase II: Arm A (Bevacizumab + Dasatinib) | 67 | 84 | 432 |
| other | Hemoglobin decreased | Blood and lymphatic system disorders | Phase II: Arm B (Bevacizumab + Placebo) | 14 | 39 | 38 |
| other | Atrial fibrillation | Cardiac disorders | Phase I: Dose Level 0 | 0 | 3 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Phase I: Dose Level 1 | 0 | 4 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Phase I: Dose Level 2 | 0 | 3 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Phase I: Dose Level 3 | 0 | 6 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Phase II: Arm A (Bevacizumab + Dasatinib) | 1 | 84 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Phase II: Arm B (Bevacizumab + Placebo) | 0 | 39 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase I: Dose Level 0 | 0 | 3 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase I: Dose Level 1 | 0 | 4 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase I: Dose Level 2 | 0 | 3 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase I: Dose Level 3 | 0 | 6 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase II: Arm A (Bevacizumab + Dasatinib) | 0 | 84 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase II: Arm B (Bevacizumab + Placebo) | 1 | 39 | 1 |
| other | Hearing test abnormal | Ear and labyrinth disorders | Phase I: Dose Level 0 | 0 | 3 | 0 |
| other | Hearing test abnormal | Ear and labyrinth disorders | Phase I: Dose Level 1 | 0 | 4 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00892177/events